GAITHERSBURG, Md.–(BUSINESS WIRE)–Valted Seq, a biotechnology company focused on the genetic elucidation of neurodegenerative disease pathways to accelerate development of new therapeutics and diagnostics, today announced the completion of a seed fundraising round totaling $10.5 million. Dongkoo Bio&Pharma Co. Ltd. led the financing round which also included new investor OV Principal Investments, LLC and several independent investors. Co-Founder D&D Pharmatech was the pre-seed investor at $7 million.
“Today’s announcement of our seed funding reflects the interest and excitement of international investors and further validates our compelling technology and vision,” said Nina Urban, Valted Seq’s interim CEO. “This financing will accelerate the development of our HiF-Seq platform, generating the largest single-nuclei sequence database for Parkinson’s disease. Interrogating the transcriptomic fingerprints of this highly complex and poorly understood disease will lead to validated drug targets and biomarkers.”
Read the full article at: www.businesswire.com
